ACTG175 {speff2trial} | R Documentation |
AIDS Clinical Trials Group Study 175
Description
ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with
combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human
immunodeficiency virus type I whose CD4 cell counts were between 200 and 500 per cubic millimeter.
Usage
data(ACTG175)
Format
A data frame with 2139 observations on the following 24 variables:
pidnum
- patient's ID number
age
- age in years at baseline
wtkg
- weight in kg at baseline
hemo
- hemophilia (0=no, 1=yes)
homo
- homosexual activity (0=no, 1=yes)
drugs
- history of intravenous drug use (0=no, 1=yes)
karnof
- Karnofsky score (on a scale of 0-100)
oprior
- non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)
z30
- zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)
zprior
- zidovudine use prior to treatment initiation (0=no, 1=yes)
preanti
- number of days of previously received antiretroviral therapy
race
- race (0=white, 1=non-white)
gender
- gender (0=female, 1=male)
str2
- antiretroviral history (0=naive, 1=experienced)
strat
- antiretroviral history stratification (1='antiretroviral naive', 2='> 1 but <=q 52 weeks of prior
antiretroviral therapy', 3='> 52 weeks')
symptom
- symptomatic indicator (0=asymptomatic, 1=symptomatic)
treat
- treatment indicator (0=zidovudine only, 1=other therapies)
offtrt
- indicator of off-treatment before 96pm5 weeks (0=no,1=yes)
cd40
- CD4 cell count at baseline
cd420
- CD4 cell count at 20pm5 weeks
cd496
- CD4 cell count at 96pm5 weeks (=
NA
if missing)
r
- missing CD4 cell count at 96pm5 weeks (0=missing, 1=observed)
cd80
- CD8 cell count at baseline
cd820
- CD8 cell count at 20pm5 weeks.
Details
There are two treatment arms in the data set, zidovudine monotherapy and the mixture of all other study
therapies. The data set includes the following post-randomization covariates: CD4 and CD8 cell count at 20pm5
weeks and the indicator of whether or not the patient was taken off-treatment before 96pm5 weeks.
References
Hammer SM, et al. (1996), "A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter.", New England Journal of Medicine,
335:1081–1090.
[Package
speff2trial version 1.0.0
Index]